As both MEK and mTOR inhibitors promote a decrease in HCC cell proliferation both in vivo and in vitro, the data suggest that these inhibitors could be combined with other small molecules, which may be more potent in inducing apoptosis, for HCC treatment. This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.